Subcutaneous implantation of osmotic minipumps was employed to deliver recombinant FGF23 (rFGF23) in CKD rats for 4 weeks, successfully inducing sustained rFGF23 overexpression (Fig. 3A). Here, FGF23 is linked to chronic kidney disease.